Surgical margin width for liver-only colorectal cancer spread
Part of Cancer clinical trials.
This trial tests whether a wider surgical margin (at least 7mm) during liver surgery improves survival and reduces cancer return in patients whose colorectal cancer has spread to the liver but not elsewhere. It aims to remove all visible liver tumors with a safe margin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Able to have daily activities without help (ECOG 0-1)
- Colorectal cancer that has spread to the liver, confirmed by biopsy or other tests
- Primary colorectal tumor already removed or will be removed within 4-6 weeks after liver surgery
- 5 or fewer liver tumors
- No cancer spread outside the liver, or any such spread has been fully removed
- Surgeon believes all liver tumors can be completely removed with a margin of at least 7mm
- Good liver function (Child-Pugh A) and enough remaining liver after surgery (≥30%)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different types of liver surgery for people with colorectal cancer that has spread to the liver and who have specific genetic changes or a right-sided primary tumor. You will be randomly assigned to one surgery type, and researchers will track how well you do over time to see if one approach is better.
This study looks at your tumor's genetic makeup and a blood test after surgery to better predict if colorectal cancer that spread to the liver might come back early. The goal is to personalize follow-up care and potentially guide additional treatments.
This trial tests whether treating liver tumors with surgery or ablation can help people whose colorectal cancer has spread to the liver and other organs. It may be an option if you've had only 1 or 2 types of chemotherapy and your non-liver metastases are stable.
This trial compares different orders of surgery for people with colorectal cancer that has spread to the liver. It looks at which approach gives better outcomes, quality of life, and value for money.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial tests whether treating all liver tumors with surgery, ablation, or radiation is better than continuing standard chemotherapy for people with colorectal cancer that has spread only to the liver. It's for those whose liver tumors have been controlled by initial chemotherapy and are considered removable.
Hear when a new Oncology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.